Editorial
doi: 10.1001/jama.2024.9104.
Tirzepatide-New Evidence for the Treatment of Obesity From China
Affiliations
- PMID: 38819984
- DOI: 10.1001/jama.2024.9104
Item in Clipboard
Editorial
Tirzepatide-New Evidence for the Treatment of Obesity From China
JAMA.
.
No abstract available
Comment on
-
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.JAMA. 2024 Aug 20;332(7):551-560. doi: 10.1001/jama.2024.9217. JAMA. 2024. PMID: 38819983 Free PMC article. Clinical Trial.
Similar articles
-
Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis.N Engl J Med. 2024 Jul 25;391(4):371-372. doi: 10.1056/NEJMe2406487. N Engl J Med. 2024. PMID: 39047246 No abstract available.
-
Table: GLP-1 and GIP/GLP-1 receptor agonists for chronic weight management.Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-e2. doi: 10.58347/tml.2024.1708d. Med Lett Drugs Ther. 2024. PMID: 39137182 Review. No abstract available.
-
Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity-Reply.JAMA. 2024 May 21;331(19):1676. doi: 10.1001/jama.2024.2603. JAMA. 2024. PMID: 38630499 No abstract available.
-
Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity.JAMA. 2024 May 21;331(19):1673-1676. doi: 10.1001/jama.2024.2600. JAMA. 2024. PMID: 38630501 No abstract available.
-
Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future.Endocrine. 2024 Jun;84(3):822-835. doi: 10.1007/s12020-024-03757-9. Epub 2024 Mar 12. Endocrine. 2024. PMID: 38472620 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
